Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NHS7108 versus Zenpep in adults with exocrine pancreatic insufficiency
2025-521816-20-00Phase 2Authorised
- Sponsor
- Aimmune Therapeutics
- Start
- Jun 2026
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of CDX-7108 in exocrine pancreatic insufficiency (EPI) (2 arms), sponsored by Aimmune Therapeutics. Primary endpoints: Number of participants reporting 1 or more adverse events, Change from baseline in safety parameters after 14-day NHS7108 treatment and 1 more. Planned start Jun 2026; status: authorised.
02
Drugs
CDX-7108
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on 2025-521816-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521816-20-00.